MINERALYS THERAPEUTICS, INC. Increase (Decrease) in Accrued Interest Receivable, Net
MINERALYS THERAPEUTICS, INC. (MLYS) reported Increase (Decrease) in Accrued Interest Receivable, Net of -$336.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2026-06-30 was -$47.00K, a 200.00% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2026-03-31 was -$289.00K.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-12-31 was $181.00K.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-09-30 was -$10.00K.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2025 was $166.00K.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2024 was -$424.00K, a 219.44% decline from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2023 was $355.00K.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$336.00K 10-Q · filed 2026-08-11 | -$155.00K derived: sum of 3 quarters · filed 2026-08-11 | -$165.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$289.00K 10-Q · filed 2026-05-06 | -$108.00K derived: sum of 2 quarters · filed 2026-05-06 | -$118.00K derived: sum of 3 quarters · filed 2026-05-06 | -$71.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $171.00K derived: sum of 2 quarters · filed 2026-03-12 | $218.00K derived: sum of 3 quarters · filed 2026-08-11 | $166.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $37.00K derived: sum of 2 quarters · filed 2026-08-11 | -$15.00K 10-Q · filed 2025-11-10 | -$113.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$5.00K 10-Q · filed 2026-08-11 | -$103.00K derived: sum of 3 quarters · filed 2026-08-11 | -$126.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$52.00K 10-Q · filed 2026-05-06 | -$150.00K derived: sum of 2 quarters · filed 2026-05-06 | -$173.00K derived: sum of 3 quarters · filed 2026-05-06 | -$357.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$121.00K derived: sum of 2 quarters · filed 2026-03-12 | -$305.00K derived: sum of 3 quarters · filed 2026-03-12 | -$424.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$207.00K derived: sum of 2 quarters · filed 2025-11-10 | -$326.00K 10-Q · filed 2025-11-10 | -$626.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$303.00K 10-Q · filed 2025-08-12 | -$603.00K derived: sum of 3 quarters · filed 2025-08-12 | -$384.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$119.00K 10-Q · filed 2025-05-12 | -$419.00K derived: sum of 2 quarters · filed 2025-05-12 | -$200.00K derived: sum of 3 quarters · filed 2025-05-12 | -$34.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$81.00K derived: sum of 2 quarters · filed 2025-02-12 | $85.00K derived: sum of 3 quarters · filed 2025-02-12 | $355.00K 10-K · filed 2025-02-12 |
| 2023-09-30 | $219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $385.00K derived: sum of 2 quarters · filed 2024-11-12 | $655.00K 10-Q · filed 2024-11-12 | $655.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $436.00K 10-Q · filed 2024-08-13 | $436.00K derived: sum of 3 quarters · filed 2024-08-13 | $436.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $270.00K 10-Q · filed 2024-05-09 | $270.00K derived: sum of 2 quarters · filed 2024-05-09 | $270.00K derived: sum of 3 quarters · filed 2024-05-09 | $270.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |